Although the evidence of EVs derived from ALL MSCs is limited, it has been shown that galectin-3, present in MSC EVs, favours its own expression in AML cells with a reduced therapy sensitivity in AML cells via Wnt/β-catenin signalling [241]. This evidence concerns the gene LGALS3 and acute myeloid leukemia.